NDAORALTABLET
Approved
Sep 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAXIPAM (halazepam) is an oral benzodiazepine tablet approved in 1981 by Merck & Co. for anxiety disorders. It works by enhancing GABAergic neurotransmission in the central nervous system to reduce anxiety symptoms. Halazepam is a small-molecule CNS depressant with intermediate onset and duration of action.
LOE Approaching
This mature, near-LOE product likely operates with a small, maintenance-focused team focused on retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PAXIPAM offers limited career growth and visibility given its mature, LOE-approaching status and minimal linked job openings. This role is suitable for professionals seeking stable, lower-complexity portfolio management focused on compliance and revenue protection rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on PAXIPAM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.